LABORATORIO REIG JOFRE (ES:RJF) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Reig Jofre, a pharmaceutical company listed on the Spanish stock exchange, has reported a robust financial performance for Q3 2024, with a 7% rise in revenues and a 10% increase in EBITDA, driven by international market growth and investments in industrial capacity. The company’s operating profit surged by 22%, supported by the success of its Specialty Pharmacare and Pharmaceutical Technologies divisions, alongside strategic investments totaling €13.6 million. Despite inflationary pressures, the company maintained a stable debt/EBITDA ratio and anticipates continued profitability through its global expansion and product optimization strategies.
For further insights into ES:RJF stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money